标题
Optimal management of hormone receptor positive metastatic breast cancer in 2016
作者
关键词
-
出版物
Therapeutic Advances in Medical Oncology
Volume 7, Issue 6, Pages 304-320
出版商
SAGE Publications
发表日期
2015-10-20
DOI
10.1177/1758834015608993
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2.
- (2017) Gabriel N. Hortobagyi et al. JOURNAL OF CLINICAL ONCOLOGY
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
- (2015) N. I. Cherny et al. ANNALS OF ONCOLOGY
- Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
- (2015) Ilenia Migliaccio et al. BMC Medicine
- Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer
- (2015) Gayathri Nagaraj et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study
- (2015) Miguel Martín et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- (2015) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- The impact of tumor stroma on drug response in breast cancer
- (2015) Jürgen Dittmer et al. SEMINARS IN CANCER BIOLOGY
- Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer
- (2014) I. Treilleux et al. ANNALS OF ONCOLOGY
- Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial†
- (2014) J. Bines et al. ANNALS OF ONCOLOGY
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow
- (2014) Glenn Deng et al. BMC CANCER
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
- (2014) F. Cardoso et al. BREAST
- The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer
- (2014) Eva Ciruelos et al. BREAST
- Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy
- (2014) Y Chavarri-Guerra et al. BRITISH JOURNAL OF CANCER
- Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients withPIK3CAmutant advanced solid tumors: preliminary efficacy and safety in patients withPIK3CAmutant ER-positive (ER+) metastatic breast cancer (MBC)
- (2014) D Juric et al. CANCER RESEARCH
- Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy
- (2014) D Paul et al. CANCER RESEARCH
- A systematic review of bevacizumab efficacy in breast cancer
- (2014) Iben Kümler et al. CANCER TREATMENT REVIEWS
- A Good Drug Made Better: The Fulvestrant Dose-Response Story
- (2014) John F.R. Robertson et al. Clinical Breast Cancer
- Emergence of Constitutively Active Estrogen Receptor- Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer
- (2014) R. Jeselsohn et al. CLINICAL CANCER RESEARCH
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2014) Sharon H. Giordano et al. JOURNAL OF CLINICAL ONCOLOGY
- Revising the role of the androgen receptor in breast cancer
- (2014) F M Fioretti et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
- (2014) Olivia Pagani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endocrine Resistance in Breast Cancer: Focus on the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway
- (2013) Shira Peleg Hasson et al. Breast Care
- Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study
- (2013) H Iwase et al. BRITISH JOURNAL OF CANCER
- D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer
- (2013) K. Merenbakh-Lamin et al. CANCER RESEARCH
- mTOR inhibitors in advanced breast cancer: Ready for prime time?
- (2013) Lesley-Ann Martin et al. CANCER TREATMENT REVIEWS
- Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved
- (2013) Per Eystein Lønning et al. ENDOCRINE-RELATED CANCER
- Endocrine Therapy for Advanced/Metastatic Breast Cancer
- (2013) Gaia Schiavon et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor
- (2013) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
- (2013) Stephen RD Johnston et al. LANCET ONCOLOGY
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
- (2013) Sherene Loi et al. PLoS One
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts
- (2013) Shunqiang Li et al. Cell Reports
- The sequential use of endocrine treatment for advanced breast cancer: where are we?
- (2012) C. Barrios et al. ANNALS OF ONCOLOGY
- Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study
- (2012) Irene Kuter et al. BREAST CANCER RESEARCH AND TREATMENT
- Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
- (2012) Andrea Cavazzoni et al. CANCER LETTERS
- FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
- (2012) Rita S. Mehta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting apoptosis pathways in cancer stem cells
- (2011) Michele Signore et al. CANCER LETTERS
- Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
- (2011) C. Thangavel et al. ENDOCRINE-RELATED CANCER
- Incidence of Breast Cancer in the United States: Current and Future Trends
- (2011) W. F. Anderson et al. JNCI-Journal of the National Cancer Institute
- PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer
- (2010) Ruth E. Board et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase II Parallel Group Study Showing Comparable Efficacy Between Premenopausal Metastatic Breast Cancer Patients Treated With Letrozole Plus Goserelin and Postmenopausal Patients Treated With Letrozole Alone As First-Line Hormone Therapy
- (2010) In Hae Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptor–Positive, Metastatic Carcinoma of the Breast in Premenopausal Women
- (2010) Robert. W. Carlson et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
- (2010) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
- (2009) Matthew J. Ellis et al. BREAST CANCER RESEARCH AND TREATMENT
- PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer
- (2009) R. J. Crowder et al. CANCER RESEARCH
- Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor–Positive, Aromatase Inhibitor–Resistant Advanced Breast Cancer
- (2009) Matthew J. Ellis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study
- (2009) John F.R. Robertson et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- (2009) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
- (2008) Robert J. Paridaens et al. JOURNAL OF CLINICAL ONCOLOGY
- Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT
- (2008) Stephen Chia et al. JOURNAL OF CLINICAL ONCOLOGY
- Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter?
- (2008) W. R. Miller et al. ONCOLOGIST
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now